BioNTech is expanding its oncology pipeline with FixVac, iNeST, and BNT327 for individualized cancer treatments. Read why I ...

German COVID-19 vaccine maker BioNTech on Monday said that its 2025 revenues would likely fall to between 1.7 billion euros ...

BioNTech SE exceeded earnings expectations with strong oncology pipeline development, despite reduced vaccine revenue.

BioNTech SE ( NASDAQ:BNTX ) just released its full-year report and things are looking bullish. Results overall ...

BioNTech shares fell Monday, as the COVID-19 vaccine maker’s soft outlook offset better-than-expected quarterly results.

Analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of BioNTech in a research report ...

BioNTech (BNTX) stock slid lower today after the German biotechnology company reported its Q4 2024 earnings. The company ...

Ugur Sahin; Chief Executive Officer, Member of the Management Board; Biontech SE Oezlem Tuereci; Chief Medical Office, Member of the Management Board; Biontech SE Welcome to BioNTech's fourth ...

BioNTech's Q4 revenue beat estimates despite lower COVID-19 vaccine sales. The company advances oncology programs, with key ...

The latest analyst coverage could presage a bad day for BioNTech SE (NASDAQ:BNTX), with the analysts making across-the-board cuts to their statutory estimates that might leave shareholders a little ...

Fintel reports that on March 13, 2025, Citigroup initiated coverage of BioNTech SE - Depositary Receipt () (NasdaqGS:BNTX) ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...